Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

Inclusion Criteria:

- Has completed study 3200K1-4000-WW, including 2 weeks of therapy and completion of all
post baseline efficacy, safety, and health outcomes assessments.

- Is receiving opioids on a regular schedule, not just as needed to control pain.

- Likely to continue to need treatment of OIC for the duration of participation in the
study.

Exclusion Criteria:

- Has a suspected mechanical gastrointestinal obstruction, fecal impaction, or
clinically important active diverticular disease as determined by the investigator.

- Currently using an opioid antagonist or partial antagonist.

- Has any other clinically important abnormalities such that risk to patient of
participation outweighs the potential benefit of therapy as determined by the
investigator